Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Isis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY...

  • Tuesday, October 23, 2012, 3:06 PM ET
    Isis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY +0.2%) as its portion of the upfront fees in ALNY's recently announced collaboration with Genzyme. In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments. Already this year, Isis has earned $2.7M from Alnylam as a result of licenses that were supported by Isis' patents.
Track new comments on this story

This news story has 1 comment:

  •  
    Well, sounds nice, but, Is ISIS really going to make THE GRADE (like A+) in the next decade! My history with this company goes back 15 years or so and I really haven't seen much bottom line progress to shareholders; traders? yea ... sometimes, but not consequentially.
    23 Oct 2012, 06:22 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »